作者
Leyre Zubiri, Gabriel E Molina, Meghan J Mooradian, Justine Cohen, Sienna M Durbin, Laura Petrillo, Genevieve M Boland, Dejan Juric, Michael Dougan, Molly F Thomas, Alex T Faje, Michelle Rengarajan, Amanda C Guidon, Steven T Chen, Daniel Okin, Benjamin D Medoff, Mazen Nasrallah, Minna J Kohler, Sara R Schoenfeld, Rebecca K Leaf, Meghan E Sise, Tomas G Neilan, Daniel A Zlotoff, Jocelyn R Farmer, Aditya Bardia, Ryan J Sullivan, Steven M Blum, Yevgeniy R Semenov, Alexandra-Chloé Villani, Kerry L Reynolds
发表日期
2021
期刊
Journal for immunotherapy of cancer
卷号
9
期号
9
出版商
BMJ Publishing Group
简介
Background
In 2017, Massachusetts General Hospital implemented the Severe Immunotherapy Complications (SIC) Service, a multidisciplinary care team for patients hospitalized with immune-related adverse events (irAEs), a unique spectrum of toxicities associated with immune checkpoint inhibitors (ICIs). This study’s objectives were to evaluate the intervention’s (1) effect on patient outcomes and healthcare utilization, and (2) ability to collect biological samples via a central infrastructure, in order to study the mechanisms responsible for irAEs.
Methods
A hospital database was used to identify patients who received ICIs for a malignancy and were hospitalized with severe irAEs, before (April 2, 2016–October 3, 2017) and after (October 3, 2017–October 24, 2018) SIC Service initiation. The primary outcome was readmission rate after index hospitalization. Secondary outcomes included length of stay (LOS) for …
引用总数
20212022202320241669